Clinical Instructor and Postdoctoral Fellow University of Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania
Current therapies for autoimmunity cause significant morbidity and mortality. Adoptive immunotherapy using genetically engineered T cells has led to long-term remissions of B cell leukemias and lymphomas, raising the question of whether the approach can be modified to target autoreactive B and T cells to induce durable remissions of autoimmunity. This session will review antigen-specific approaches to modify immune cells to treat autoimmune disease. We will focus on recent studies that aim to eliminate or suppress autoimmunity by targeting the disease-causing B or T cells through their B cell receptor or T cell receptor specificities.
Learning Objectives:
Establish knowledge about T cell engineering
Gain insight into differences in T cell engineering for oncologic versus autoimmune applications
Provide an overview on ongoing clinical trials for T cell mediated immunotherapy in autoimmune conditions